NanoBio, GSK Leave Rx Drug Path To Take "Remarkable" Cold Sore Med OTC
This article was originally published in The Rose Sheet
Executive Summary
Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow, aiming straight for the OTC market with the help of GlaxoSmithKline